IN10018
IN10018 is a pharmaceutical drug with 10 clinical trials. Currently 7 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
8
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
66.7%
2 of 3 finished
33.3%
1 ended early
7
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
IN10018 Combination Therapy in Previously-treated Solid Tumors
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Clinical Trials (10)
IN10018 Combination Therapy in Previously-treated Solid Tumors
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10